Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UBX

UNITY Biotechnology (UBX) Stock Price, News & Analysis

UNITY Biotechnology logo

About UNITY Biotechnology Stock (NASDAQ:UBX)

Key Stats

Today's Range
$0.20
$0.20
50-Day Range
$0.18
$0.88
52-Week Range
$0.20
$1.23
Volume
N/A
Average Volume
808,608 shs
Market Capitalization
$3.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UBX Stock News Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More Headlines

UBX Stock Analysis - Frequently Asked Questions

UNITY Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings data on Tuesday, April, 22nd. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43).

UNITY Biotechnology shares reverse split on the morning of Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

UNITY Biotechnology (UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

Company Calendar

Last Earnings
4/22/2025
Today
7/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UBX
CIK
1463361
Fax
N/A
Employees
60
Year Founded
2009

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.99 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-246.82%
Return on Assets
-58.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
1.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
0.51

Miscellaneous

Outstanding Shares
17,212,000
Free Float
16,214,000
Market Cap
$3.44 million
Optionable
Optionable
Beta
0.92

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:UBX) was last updated on 7/30/2026 by MarketBeat.com Staff.
From Our Partners